Status:
COMPLETED
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate
Lead Sponsor:
GlaxoSmithKline
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE4
Brief Summary
This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done during the study. Study...
Detailed Description
A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Persistent Asthma, ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of persistent asthma for 3 months.
- Use of short-acting beta-agonist medication like VENTOLIN.
- Exclusion criteria:
- Hospitalization for asthma 6 months before study.
- Other serious diseases like congestive heart failure, uncontrolled hypertension, TB.
- Current use of inhaled or oral corticosteroids.
Exclusion
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
547 Patients enrolled
Trial Details
Trial ID
NCT00102882
Start Date
October 1 2004
End Date
January 1 2007
Last Update
February 3 2017
Active Locations (91)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Mobile, Alabama, United States, 36608
2
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
3
GSK Investigational Site
Fresno, California, United States, 93720
4
GSK Investigational Site
Fullerton, California, United States, 92835